Secretin Synthetic Human
drugOn this page
Also known as ChirhostimHuman secretinSecretin (human)Secretin (human), acetate (salt)Secretin acetate humanSecretin humanSecretin human acetateSecretin human pentaacetateSecretina humanaSecretine humaineSynthetic human secretin
Summary
Secretin Synthetic Human (CHEMBL1201488) is an approved protein targeting SCTR; indicated across 2 conditions including autism and obsessive-compulsive disorder.
At a glance
- Status: Approved (max clinical phase 4)
- Modality: Protein
- Targets: 1 (SCTR)
- Indications: 2 conditions
- Clinical trials: 11
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL1201488 |
| Name | Secretin Synthetic Human |
| Type | Protein |
| Max phase | 4 |
Also known as: Chirhostim, Human secretin, Secretin (human), Secretin (human), acetate (salt), Secretin acetate human, Secretin human, Secretin human acetate, Secretin human pentaacetate, Secretin synthetic human, Secretina humana, Secretine humaine, Synthetic human secretin
Targets
Targets
Primary targets (GtoPdb curated mechanism): the Cancer dependency column is the DepMap CRISPR fitness signal (% of screened cell lines dependent on the target).
| Gene | Target | Action | pAffinity | Cancer dependency | UniProt |
|---|---|---|---|---|---|
| SCTR | secretin receptor | Full agonist | 9.7 | 0.5% | P47872 |
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
Aggregated over 1 target gene(s): SCTR.
Top Reactome pathways
7 total, by targets touching each:
| Pathway | Targets | Genes |
|---|---|---|
| Signal Transduction | 1 | SCTR |
| Signaling by GPCR | 1 | SCTR |
| Class B/2 (Secretin family receptors) | 1 | SCTR |
| GPCR downstream signalling | 1 | SCTR |
| G alpha (s) signalling events | 1 | SCTR |
| Glucagon-type ligand receptors | 1 | SCTR |
| GPCR ligand binding | 1 | SCTR |
Dominant GO biological processes
| GO term | Targets |
|---|---|
| diet induced thermogenesis | 1 |
| cell surface receptor signaling pathway | 1 |
| G protein-coupled receptor signaling pathway | 1 |
| adenylate cyclase-modulating G protein-coupled receptor signaling pathway | 1 |
| adenylate cyclase-activating G protein-coupled receptor signaling pathway | 1 |
| intracellular water homeostasis | 1 |
| response to nutrient levels | 1 |
| regulation of appetite | 1 |
| regulation of synaptic plasticity | 1 |
| signal transduction | 1 |
Indications & clinical
Indications
2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| autism | 3 | MONDO:0005260 | EFO:0003758 |
| obsessive-compulsive disorder | 2 | MONDO:0008114 | EFO:0004242 |
Clinical trials
Total trials: 11.
Phase distribution
| Phase | Trials |
|---|---|
| Not specified | 4 |
| PHASE1/PHASE2 | 3 |
| PHASE3 | 2 |
| PHASE2/PHASE3 | 1 |
| EARLY_PHASE1 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT01087801 | PHASE3 | COMPLETED | A Study of Synthetic Human Secretin (ChiRhoStim®) Administered Intravenously to Stimulate Exocrine Pancreas Fluid Secretion for Collection Via Endoscope and Laboratory Analysis of DNA Markers |
| NCT03290846 | PHASE2/PHASE3 | COMPLETED | Secretin Activates Human Brown Fat and Induces Satiation. |
| NCT04231279 | PHASE3 | TERMINATED | Recurrent Abdominal Pain and Exocrine Pancreatic Insufficiency |
| NCT00587132 | PHASE1/PHASE2 | TERMINATED | Secretin (ChiRhoStim) Pancreas Perfusion for Pancreatic Adenocarcinoma |
| NCT01265875 | PHASE1/PHASE2 | COMPLETED | Secretin Infusion for Pain Due to Chronic Pancreatitis |
| NCT03617861 | PHASE1/PHASE2 | COMPLETED | Effect of Secretin in Functional Dyspepsia and Healthy Subjects |
| NCT01371240 | EARLY_PHASE1 | WITHDRAWN | Secretin-Assisted Computed Tomography Scan and Magnetic Resonance Imaging in Improving Pancreatic Tumor Conspicuity |
| NCT01094535 | Not specified | WITHDRAWN | Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery |
| NCT01094561 | Not specified | COMPLETED | Secretin-Stimulated Magnetic Resonance Cholangiopancreatography (S-MRCP) in Pancreatic Patients |
| NCT01094600 | Not specified | WITHDRAWN | Comparison of Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) to Endoscopic Pancreatic Function Test (ePFT) in Diagnosing Pancreatic Exocrine Insufficiency |
| NCT03404661 | Not specified | COMPLETED | Optical and Biochemical Biomarkers in Early Pancreatic Cancer |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
Molecules sharing ≥1 of this drug’s curated primary targets, merged from two biobtree sources and ranked by shared-target count, then clinical phase: ChEMBL clinical-stage candidates (development phase ≥2) and PubChem drug-class bioactivity (approved / known drugs acting on the target). Deduplicated by drug name; the drug’s own salt forms are excluded. Note: for a drug with few primary targets a shared-target match can reflect off-target / promiscuous binding rather than the same therapeutic mechanism — the phase ordering surfaces bona-fide therapeutics first.
1 molecules share ≥1 primary target. Top 1 by shared-target count:
| Molecule | Source | Status | Shared targets |
|---|---|---|---|
| SECRETIN | ChEMBL | Phase 4 (approved) | SCTR |